Table 6.

Impact of expression of PD-L1 on disease-free and overall survival tested by log-rank analysis

Parameters	Number of patients /recurrence/death	Disease-free survival		Overall survival
		Mean survival (95 % CI) months	p value	Mean survival (95 % CI) months	p value
PD-L1 (28-8) (T)			N/A		0.967
Negative	191/16/17	N/A		91 (87–95)
Positive	27/0/2	N/A		59 (54–64)
PD-L1 (E1L3N) (T)			N/A		0.647
Negative	186/16/17	N/A		90 (86–95)
Positive	32/0/2	N/A		91 (84–98)
PD-L1 (28-8) (I)			0.043		0.021
Negative	138/14/17	89 (84–93)		87 (82–92)
Positive	80/2/2	97 (94–100)		97 (94–100)
PD-L1 (E1L3N) (I)			0.761		0.255
Negative	136/11/15	91 (87–95)		88 (84–93)
Positive	82/5/4	94 (89–98)		95 (90–99)
PD-L1 (SP142) (I)			0.191		0.387
Negative	176/15/17	90 (86–94)		89 (85–93)
Positive	42/1/2	97 (93–101)		95 (89–100)

Italics represents p < 0.05

T tumor cell, I immune cell